NEW YORK, May 30, 2017 /PRNewswire/ --
On Friday, May 26, 2017, US markets saw a mixed session as 4 sectors closed in green, 2 sectors finished in red, and 3 sectors ended flat for the day. Major US indices were also mixed at the close of last Friday's session. The NASDAQ Composite ended the at 6,210.19, up 0.08%; the Dow Jones Industrial Average edged 0.01% lower, to finish at 21,080.28; and the S&P 500 closed at 2,415.82, up 0.03%. This Tuesday morning, Stock-Callers.com looks at the performance of these four Biotechnology stocks: Corcept Therapeutics Inc. (NASDAQ: CORT), Curis Inc. (NASDAQ: CRIS), OvaScience Inc. (NASDAQ: OVAS), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). You can access our complimentary research reports on these stocks now at:
Last Friday, shares in Menlo Park, California headquartered Corcept Therapeutics Inc. ended the session 5.40% higher at $12.29. The stock recorded a trading volume of 1.26 million shares, which was above its three months average volume of 1.04 million shares. The Company's shares have surged 31.58% in the last month, 36.10% in the previous three months, and 69.28% since the start of this year. The stock is trading 18.22% and 49.24% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Corcept Therapeutics, which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have a Relative Strength Index (RSI) of 66.25. Visit us today and download your complete report on CORT for free at:
Lexington, Massachusetts headquartered Curis Inc.'s stock gained 1.18%, to close the day at $1.72 with a total trading volume of 332,662 shares. The Company's shares are trading 28.16% below their 50-day moving average. Shares of the Company, which engages in the discovery and development of drug candidates for the treatment of human cancers in the US, have an RSI of 30.75. The complimentary research report on CRIS can be accessed at:
Shares in Waltham, Massachusetts headquartered OvaScience Inc. recorded a trading volume of 190,979 shares at the close of the last trading session. The stock ended the day 1.53% lower at $1.29. The Company's shares are trading below their 50-day moving average by 15.47%. Furthermore, shares of OvaScience, which discovers, develops, and commercializes fertility treatment options for women worldwide, have an RSI of 30.01. Register for free on Stock-Callers.com and download the PDF research report on OVAS at:
Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s shares finished Friday's session flat at $14.05. A total volume of 440,081 shares was traded. The stock is trading below its 50-day moving average by 1.59%. Furthermore, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 45.05. Get free access to your research report on VNDA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA